Skip to main content

Menveo Dosage

Generic name: NEISSERIA MENINGITIDIS GROUP A CAPSULAR OLIGOSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 10ug in 0.5mL; NEISSERIA MENINGITIDIS GROUP C CAPSULAR OLIGOSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 5ug in 0.5mL, NEISSERIA MENINGITIDIS GROUP W-135 CAPSULAR OLIGOSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 5ug in 0.5mL, NEISSERIA MENINGITIDIS GROUP Y CAPSULAR OLIGOSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 5ug in 0.5mL
Dosage form: injection
Drug class: Bacterial vaccines

Medically reviewed by Drugs.com. Last updated on Mar 31, 2025.

For intramuscular injection only.

MENVEO Presentations

MENVEO is supplied in two presentations, a two-vial presentation and a one-vial presentation.

Two-Vial Presentation

The two-vial presentation includes a vial with a gray cap containing the MenCYW-135 liquid conjugate component and a vial with an orange cap containing the MenA lyophilized conjugate component. The contents of the vials must be combined to form MENVEO prior to administration. This presentation is for use in individuals 2 months through 55 years of age.

One-Vial Presentation

The one-vial presentation contains MENVEO in a single vial with a pink cap and does not require reconstitution before use. This presentation is for use in individuals 10 through 55 years of age.

Preparation

Reconstitution Instructions for MENVEO Two-Vial Presentation

Use the MenCYW-135 liquid conjugate component (Vial 1, gray cap) to reconstitute the MenA lyophilized conjugate component (Vial 2, orange cap) to form MENVEO. Invert Vial 2 and shake well until the lyophilized conjugate component is dissolved. After reconstitution, withdraw 0.5 mL from the vial containing the reconstituted vaccine. See Figures 1 through 4.

​Administer MENVEO immediately after reconstitution.

Menveo Figure 1 Menveo Figure 2 Menveo Figure 3 Menveo Figure 4

Figure 1. Cleanse both vial stoppers. Using a sterile needle and sterile graduated syringe, withdraw the entire contents of Vial 1 containing the MenCYW-135 liquid conjugate component while slightly tilting the vial.

Figure 2. Slowly transfer entire contents of the syringe into Vial 2 containing the MenA lyophilized conjugate component.

Figure 3. Invert the vial and shake well until lyophilized conjugate component is completely dissolved.

Figure 4. After reconstitution, withdraw 0.5 mL from the vial containing the reconstituted vaccine.

Instructions for MENVEO One-Vial Presentation

The MENVEO presentation that is supplied in a single vial with a pink cap does NOT require reconstitution. Withdraw 0.5 mL from the vial.

Administration

MENVEO is a clear, colorless solution, free from visible foreign particles. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If any of these conditions exist, MENVEO should not be administered.

Administer a single 0.5-mL dose by intramuscular injection.

Dosing Schedule

The dosing schedule is as follows:

Primary Vaccination

Table 1. Dosing Schedule for MENVEO Primary Vaccination
MENVEO Two-Vial Presentation

Infants Aged 2 Months

4-dose series at 2, 4, 6, and 12 months of age

Children Aged 7 through 23 Months

2-dose series with the second dose administered in the second year of life and at least 3 months after the first dose

Children Aged 2 through 10 Years

A single dose

For children aged 2 through 5 years at continued high risk of meningococcal disease, a second dose may be administered 2 months after the first dose.

Adolescents and Adults Aged 11 through 55 Years

A single dose

MENVEO One-Vial Presentation

Adolescents and Adults Aged 10 through 55 Years

A single dose

Booster Vaccination

Adolescents and Adults Aged 15 through 55 Years: A single booster dose of MENVEO using either the two-vial presentation or the one-vial presentation may be administered to individuals who are at continued risk for meningococcal disease if at least 4 years have elapsed since a prior dose of a meningococcal (serogroups A, C, Y, W-135) conjugate vaccine.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer